After Kodak debacle, US lends $1.1B to a synthetic biology company and their big Covid-19, mRNA plans
In mid-August, as Kodak’s $765 million government-backed push into drug manufacturing slowly fell apart in national headlines, Ginkgo Bioworks CEO Jason Kelly got a message from his company’s government liaison: HHS wanted to know if they, too, might want a loan.
The government’s decision to lend Kodak three quarters of a billion dollars raised eyebrows because Kodak had never made drugs before. But Ginkgo, while not a manufacturing company, had spent the last decade refining new ways to produce materials inside cells and building automated facilities across Boston.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,200+ biopharma pros reading Endpoints daily — and it's free.